Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656645 | 0.90 | DPP4 (0.37) | DPP4EPHX2PTPN2PTPN1CDC25B | |
| SCHEMBL1785284 | 0.85 | CYP3A4 (0.47) | CYP3A4CYP2C19 | |
| SCHEMBL1782898 | 0.84 | PIK3CD (0.37) | PTPN2PTPN1CDC25BIDO1ADAMTS5 | |
| SCHEMBL1782522 | 0.76 | NPC1 (0.44) | — | |
| SCHEMBL3429748 | 0.76 | DPP4 (0.39) | DPP4DPP8DPP9EPHX2DPP7 | |
| SCHEMBL1189481 | 0.73 | ALOX15 (0.44) | PTPN2PTPN1CDC25B | |
| SCHEMBL25015600 | 0.70 | PTPN2 (0.42) | PTPN2PTPN1CDC25BIDO1 | |
| SCHEMBL1785701 | 0.70 | PTPN2 (0.42) | PTPN2PTPN1CDC25BIDO1 | |
| SCHEMBL8125090 | 0.66 | PTPN2 (0.46) | PTPN2PTPN1CDC25BIDO1CYP3A4 | |
| SCHEMBL2739929 | 0.66 | MEN1 (0.48) | DPP4DPP8DPP9EPHX2DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9090576-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8716527-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | PTC THERAPEUTICS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2262508-A2 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111576-A2 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | DPP4 2737/4885DPP8 3295/4885DPP9 3196/4885 |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | DPP4 2737/4885DPP8 3295/4885DPP9 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.